List of Excipients in Branded Drug azstarys

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Corium LLC	AZSTARYS	serdexmethylphenidate and dexmethylphenidate	65038-286	CELLULOSE, MICROCRYSTALLINE	2037-12-09
Corium LLC	AZSTARYS	serdexmethylphenidate and dexmethylphenidate	65038-286	CROSPOVIDONE	2037-12-09
Corium LLC	AZSTARYS	serdexmethylphenidate and dexmethylphenidate	65038-286	FD&C BLUE NO. 1	2037-12-09
Corium LLC	AZSTARYS	serdexmethylphenidate and dexmethylphenidate	65038-286	FERROSOFERRIC OXIDE	2037-12-09
Corium LLC	AZSTARYS	serdexmethylphenidate and dexmethylphenidate	65038-286	HYPROMELLOSE	2037-12-09
Corium LLC	AZSTARYS	serdexmethylphenidate and dexmethylphenidate	65038-286	MAGNESIUM STEARATE	2037-12-09
Corium LLC	AZSTARYS	serdexmethylphenidate and dexmethylphenidate	65038-286	SILICON DIOXIDE	2037-12-09

Azstarys Excipient Strategy and Commercial Opportunities

Last updated: August 3, 2026

Azstarys uses a conventional hard-gelatin capsule platform containing serdexmethylphenidate chloride and dexmethylphenidate hydrochloride. Its commercial differentiation comes primarily from the active-ingredient combination and prodrug design, not from a novel excipient system. The main excipient opportunities are therefore incremental: pediatric administration, sprinkle performance, stability, capsule-shell design, manufacturing efficiency, and potential lifecycle formulations.

Azstarys is a Schedule II controlled substance approved by the FDA in March 2021 for attention deficit hyperactivity disorder in patients aged 6 years and older. Corium commercializes the product. The formulation contains a 70:30 molar ratio of serdexmethylphenidate to dexmethylphenidate and is available in four strengths: 26.1/5.2 mg, 39.2/7.8 mg, 52.3/10.4 mg, and 78.6/15.7 mg, expressed as serdexmethylphenidate/dexmethylphenidate hydrochloride equivalents.[1]

What excipients are used in Azstarys capsules?

FDA labeling identifies a standard solid-oral excipient system designed for capsule filling, powder flow, disintegration, lubrication, and capsule-shell processing.

Formulation component	Function in the product
Microcrystalline cellulose	Diluent and compression or fill-volume aid
Croscarmellose sodium	Superdisintegrant
Colloidal silicon dioxide	Glidant and flow-control agent
Magnesium stearate	Lubricant
Sodium lauryl sulfate	Wetting or processing aid
Talc	Glidant, anti-adherent, or processing aid
Gelatin	Hard-capsule shell
Titanium dioxide	Opacifier and colorant
FD&C Blue No. 1	Capsule colorant
Black iron oxide	Capsule colorant in designated shell components

The inactive ingredients are not the primary source of Azstarys’ clinical differentiation. The commercial value is concentrated in the active combination, release profile, dosing convenience, and the ability to administer the capsule contents with applesauce.[1]

How does the Azstarys excipient system support product performance?

The formulation has four practical objectives.

Powder handling and capsule uniformity

Azstarys is a low-dose, multi-component powder-filled capsule. Uniform distribution of dexmethylphenidate hydrochloride and serdexmethylphenidate chloride is critical because the product contains two pharmacologically related active ingredients at different dose levels.

Microcrystalline cellulose provides bulk and helps manage fill weight. Colloidal silicon dioxide improves powder flow. Magnesium stearate reduces friction during encapsulation. These excipients are widely available and familiar to contract manufacturers, reducing supply-chain and technology-transfer risk.

The main manufacturing challenge is blend uniformity rather than excipient novelty. A generic manufacturer would need to control particle-size distribution, segregation, electrostatic behavior, mixing order, lubricant exposure, and capsule-fill weight. The risk increases as the strength changes because the ratio of active material to excipient changes across the four presentations.

Rapid dispersion after administration

Croscarmellose sodium promotes rapid breakup of the capsule contents after the capsule shell dissolves. Sodium lauryl sulfate can improve wetting of hydrophobic particles, although its level and role must be controlled because excessive surfactant can affect powder flow, dissolution, or gastrointestinal tolerability.

A generic applicant would be expected to demonstrate comparable dissolution across multiple media and strengths. The excipient system does not need to be identical in an ANDA, but the proposed formulation must meet pharmaceutical equivalence and bioequivalence requirements.

Sprinkle administration

The FDA label permits the capsule to be opened and the contents sprinkled onto applesauce. The mixture must be consumed immediately without chewing, and the full amount must be taken.[1]

This administration option creates a product-development requirement that is more specific than ordinary capsule performance. The powder must:

• Remain adequately dispersed on the food vehicle.
• Avoid unacceptable grittiness or clumping.
• Maintain dose uniformity during transfer.
• Avoid excessive adhesion to the container or spoon.
• Preserve the intended exposure profile.
• Remain acceptable to pediatric patients.

Taste masking is relevant because the contents can be exposed directly in the mouth. The current label does not identify a dedicated flavor system. This leaves room for future products using taste-masking polymers, ion-exchange resins, coated particles, sweeteners, or food-compatible flavor systems, provided the formulation does not alter the pharmacokinetics or controlled-substance handling profile.

Capsule-shell differentiation

Capsule color and shell design support product identification and may reduce medication errors across four strengths. Opportunities include improved color coding, child-resistant packaging, unit-dose formats, and shell materials designed for specific patient populations.

A switch from gelatin to hypromellose could create a differentiated product for vegetarian or religious-diet markets. The change would require evaluation of moisture transmission, brittleness, dissolution, fill compatibility, and stability. A shell change alone would not necessarily create meaningful clinical differentiation, but it could support line extensions and geographic expansion.

What commercial opportunities exist for Azstarys excipients?

The strongest opportunities are in patient administration and lifecycle management rather than in replacing standard fillers and lubricants.

Pediatric taste-masking platforms

Azstarys is approved for children as young as six. Pediatric patients who cannot swallow capsules may use the applesauce administration method, but direct exposure to the powder creates palatability limitations.

A taste-masked sprinkle formulation could support:

• Better adherence among younger children.
• Administration through alternative soft foods.
• Reduced refusal after dosing.
• Potential use in patients with swallowing difficulties.
• Differentiation from standard capsule generics.

The most commercially defensible platform would preserve the existing dose and pharmacokinetic profile while improving mouthfeel and taste. Multiparticulate coating, polymeric taste barriers, or lipid-based masking systems are potential approaches. The formulation must avoid delaying or accelerating absorption of dexmethylphenidate.

Alternative food vehicles

The current label specifically identifies applesauce. A formulation validated for yogurt, pudding, juice-compatible suspensions, or other soft foods could broaden administration options. This opportunity is technically constrained because food composition affects pH, viscosity, residence time, and drug release.

A product claim based on administration with multiple foods would likely require product-specific data. The commercial value would be highest in pediatric and special-needs populations, where administration flexibility can affect persistence with therapy.

Oral suspension or sachet line extension

A ready-to-use suspension, reconstitutable powder, or unit-dose sachet could address patients who cannot swallow capsules. These products would require substantially more development than a capsule reformulation.

Key excipient requirements would include:

• Suspending agents.
• Wetting agents.
• Preservatives for multidose products.
• Buffer systems.
• Sweeteners and flavors.
• Container-closure compatibility.
• Dose-uniformity controls.
• Controlled-substance diversion controls.

A unit-dose powder sachet may be more commercially practical than a liquid because it avoids preservative use and reduces stability risks. The sachet would still need to maintain blend uniformity and prevent accidental loss of active powder.

Capsule-in-capsule or modified shell systems

A modified capsule shell could improve swallowing, reduce moisture ingress, or provide controlled opening characteristics. These systems are less attractive than taste-masked sprinkle products because they add manufacturing complexity without necessarily improving the patient experience.

Excipient supply and manufacturing services

Specialty excipient suppliers can pursue commercial opportunities through:

• Low-moisture microcrystalline cellulose grades.
• Direct-compression or high-flow diluents.
• Engineered silicon dioxide for improved powder flow.
• Low-peroxide surfactant grades.
• Functional coating polymers for taste masking.
• Hypromellose capsule shells.
• Pediatric flavor systems.
• Continuous-blending and low-dose content-uniformity services.

The opportunity is strongest for suppliers able to provide regulatory documentation, change-control support, extractables and leachables data, and multi-site supply continuity.

How strong is the formulation IP for Azstarys?

Azstarys’ principal competitive barrier is likely the active-ingredient and pharmacokinetic IP surrounding serdexmethylphenidate, rather than the use of microcrystalline cellulose, croscarmellose sodium, or magnesium stearate.

Excipient patents

The listed excipients are widely used pharmaceutical materials. Their presence alone is unlikely to support strong exclusivity. A patent position could be more defensible if it claims a specific combination involving:

• A defined particle-size distribution.
• A narrow blend-uniformity range.
• A particular dissolution profile.
• A specific coating or taste-masking architecture.
• A defined sprinkle-food interaction.
• A stability advantage.
• A manufacturing process that controls segregation or degradation.

Such claims must be assessed against prior art and actual commercial practice. Generic applicants can often avoid a narrow excipient claim by changing the excipient grade, concentration, processing order, or capsule-shell material while maintaining equivalent performance.

Active-ingredient and prodrug protection

Serdexmethylphenidate is a prodrug of dexmethylphenidate. The prodrug strategy is central to Azstarys’ differentiation and may create stronger composition-of-matter, formulation, and method-of-use barriers than the excipient platform. The FDA Orange Book is the controlling source for current listed patents and regulatory exclusivity.[2]

The commercial implication is that an excipient supplier should not assume that a technically superior excipient creates an immediate generic opportunity. An ANDA applicant must address the listed patents and any applicable regulatory exclusivity, regardless of whether it uses an alternative excipient system.

When does Azstarys lose exclusivity?

Azstarys has multiple exclusivity layers that must be analyzed separately:

Exclusivity category	Relevance to Azstarys
New chemical entity exclusivity	The product contains a prodrug active ingredient and a previously approved active component; the applicable exclusivity depends on FDA’s regulatory classification
Orange Book patent protection	Listed patents may cover the active ingredients, formulation, methods of use, or related technology
Pediatric exclusivity	FDA may grant six additional months to qualifying patents or exclusivity periods if statutory requirements are met
Orphan exclusivity	Not the principal basis of Azstarys’ ADHD approval
Regulatory exclusivity for a new formulation	Potentially relevant to future lifecycle products, not automatically available for every excipient change

The practical generic-entry date depends on the latest enforceable patent, patent-term adjustment, pediatric extension, litigation outcome, and settlement terms. An exact entry forecast should be based on the current Orange Book listing and court docket, not on the product’s 2021 approval date alone.[2,3]

What is the Orange Book and Paragraph IV risk for Azstarys?

Azstarys is an FDA-approved small-molecule capsule, so the principal generic pathway is an ANDA rather than a biosimilar application. An ANDA applicant may submit a Paragraph IV certification alleging that an Orange Book-listed patent is invalid, unenforceable, or not infringed.

A Paragraph IV challenge would create several commercial outcomes:

1. The patent holder may sue within 45 days, triggering a potential 30-month stay of approval under the Hatch-Waxman framework.
2. The ANDA applicant may obtain approval before commercial launch if patent issues are resolved or the stay expires.
3. The parties may settle on a licensed entry date.
4. A successful challenge could enable earlier generic launch.
5. A court decision could preserve the patent term and defer entry.

The likely litigation focus would be the active-ingredient and prodrug claims, dosage-form claims, and any method-of-use claims listed for ADHD treatment. Standard excipient substitutions would generally be used to avoid formulation claims where possible.

Are biosimilars a risk for Azstarys?

No. Azstarys is a small-molecule drug, not a biologic. Biosimilar litigation and the Biologics Price Competition and Innovation Act do not apply. Competitive risk comes from ANDA-approved generics, authorized generics, branded methylphenidate products, amphetamine products, and other long-acting ADHD medicines.

The most relevant competitors include Concerta, Ritalin LA, Focalin XR, Vyvanse, Adderall XR, Jornay PM, Quillivant XR, and Xelstrym. Competition is based on duration, onset, abuse-deterrence perceptions, formulation flexibility, payer coverage, and tolerability.

Which licensing and partnership issues affect Azstarys?

Corium is the commercial sponsor of Azstarys, while KemPharm developed the serdexmethylphenidate technology. The product’s commercial structure reflects a licensing and development relationship around the prodrug platform rather than an excipient-centered partnership.[4]

For excipient companies, the relevant contracting opportunities are more likely to involve:

• Preferred-supplier agreements.
• Dual-source qualification.
• Technology licenses for taste masking or modified-release coatings.
• Contract development and manufacturing.
• Pediatric formulation partnerships.
• Geographic rights for line extensions.

Any supplier proposing a new excipient platform must address controlled-substance security, validated cleaning, chain of custody, DEA requirements, and change-control obligations.

How should companies assess Azstarys’ excipient commercial opportunity?

The opportunity can be ranked as follows:

Opportunity	Commercial potential	Main barrier
Standard capsule excipient supply	Moderate	Price competition and multiple qualified suppliers
Taste-masked sprinkle capsule	High	Bioequivalence, sensory performance, and IP
Unit-dose sprinkle sachet	Moderate to high	Dose uniformity and controlled-substance controls
Oral suspension	Moderate	Stability, preservatives, packaging, and development cost
Hypromellose capsule shell	Low to moderate	Limited clinical differentiation
Novel release-controlling excipient	Moderate	Must preserve the established PK profile
Generic-compatible alternative formulation	High for ANDA developers	Patent certification and bioequivalence
Pediatric food-compatible platform	High	Food-effect and administration studies

The highest-value path is a taste-masked, pediatric-friendly sprinkle platform that preserves Azstarys’ existing pharmacokinetics. The lowest-risk path is continued supply of compendial excipients for the approved capsule, but that market is likely to be competitive and margin-sensitive.

Key Takeaways

• Azstarys uses a conventional capsule excipient system built around microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, sodium lauryl sulfate, talc, and gelatin-based capsule components.
• The product’s differentiation comes mainly from serdexmethylphenidate, dexmethylphenidate, dosing duration, and administration flexibility.
• The FDA label permits sprinkling the capsule contents on applesauce, creating a commercial opportunity for taste masking and improved pediatric acceptability.
• Generic risk is governed by ANDA and Paragraph IV pathways, not biosimilar regulation.
• Excipient patents are likely weaker than active-ingredient and prodrug patents unless they claim a specific performance, processing, stability, or taste-masking system.
• A unit-dose sprinkle product, oral suspension, or taste-masked capsule could support lifecycle management.
• Excipient suppliers with low-dose blending, pediatric palatability, coating, and controlled-substance manufacturing capabilities have the strongest partnership opportunities.

FAQs

Can Azstarys use different excipients in a generic version?

Yes. An ANDA applicant generally does not need to duplicate every inactive ingredient, provided the formulation meets pharmaceutical-equivalence, bioequivalence, quality, and safety requirements. Certain inactive ingredients may require additional justification if their amount, route, or patient exposure raises regulatory concerns.

Is Azstarys an abuse-deterrent formulation?

Azstarys contains serdexmethylphenidate, a prodrug designed to be converted to dexmethylphenidate in the body. The FDA-approved labeling describes the product’s pharmacology and controlled-substance status, but an excipient change alone would not establish abuse-deterrent labeling or claims.[1]

Can Azstarys be reformulated as a liquid?

Yes, from a development perspective, but a liquid would be a new formulation requiring extensive work on dose uniformity, stability, palatability, packaging, microbial control, and pharmacokinetics. It would not be a simple excipient substitution.

What excipient best supports Azstarys taste masking?

No single excipient is established as the preferred solution. Polymer-coated particles, ion-exchange systems, lipid barriers, and specialized pediatric flavors are candidate approaches. The selected system must preserve the product’s release and exposure profile.

Does an improved Azstarys formulation receive new patent protection?

Potentially. A new formulation may support patent claims if it delivers a non-obvious improvement in taste, stability, dissolution, administration, or pharmacokinetics. Routine substitution of one standard excipient for another is less likely to support durable patent protection.

References

1. U.S. Food and Drug Administration. (2021). Azstarys (serdexmethylphenidate and dexmethylphenidate) capsules, prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Food and Drug Administration. (2024). ANDA submissions: Refuse-to-receive standards and Paragraph IV patent certifications. FDA.

4. KemPharm, Inc. (2021). Corporate information and serdexmethylphenidate development materials. Company disclosures.